Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer surgery. It is not yet known whether epidural analgesia is more effective than patient-controlled analgesia in controlling pain in patients who have undergone surgery for gynecologic cancer.
PURPOSE: This randomized clinical trial is studying epidural analgesia to see how well it works compared to patient-controlled analgesia in treating patients who have undergone surgery for gynecologic cancer.
| Condition | Intervention |
|---|---|
|
Cervical Cancer Endometrial Cancer Fallopian Tube Cancer Ovarian Cancer Pain Perioperative/Postoperative Complications Sarcoma |
Drug: fentanyl citrate Drug: hydromorphone hydrochloride Drug: ropivacaine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Supportive Care |
| Official Title: | Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study |
- Time to return to bowel function at discharge
- Pain score daily
| Estimated Enrollment: | 224 |
| Study Start Date: | March 2005 |
OBJECTIVES:
- Determine whether the gradual weaning of an epidural opioid can shorten the duration of postoperative ileus, without worsening pain control, in patients who have undergone surgery for gynecologic cancer.
- Compare postoperative pain management in patients treated with perioperative epidural analgesia vs patient controlled analgesia.
- Compare time to ambulation, return of bowel function, and readiness for hospital discharge in patients treated with these pain management interventions.
- Compare the incidence of perioperative complications (e.g., bleeding, hypotension, thromboembolic events, pneumonia, wound infection, myocardial infection, or death) in patients treated with these pain management interventions.
OUTLINE: This is a partially randomized, double-blind, parallel-group study. Patients choose between epidural analgesia or patient controlled analgesia (PCA) for perioperative pain management. Patients for whom an epidural is contraindicated receive a PCA. Patients are assigned to 1 of 2 treatment groups. Patients in group 1 are stratified according to bowel resection surgery (yes vs no) and prior abdominal surgery (yes vs no).
Group 1 (epidural): Patients undergo placement of a thoracic epidural catheter followed by abdominal/pelvic surgery. Patients then begin an epidural infusion of ropivacaine hydrochloride and fentanyl immediately after surgery (postoperative day 0). Patients may also be supplemented with a patient controlled demand dose. The day after surgery (postoperative day 1), patients are randomized (as long as there is adequate pain control) to 1 of 2 epidural management arms.
- Arm I: Patients continue to receive the epidural infusion until they can be weaned to oral pain medication.
- Arm II: Patients undergo daily weaning of the fentanyl concentration of the epidural infusion.
- Group 2 (PCA): Patients begin PCA immediately after undergoing abdominal/pelvic surgery (postoperative day 0). Patients receive a demand schedule of hydromorphone IV until they can be weaned to oral pain medication.
In both groups, the Gynecologic Oncology pain service may make adjustments to the epidural infusion or PCA for optimal pain management until the patient can be weaned to oral pain medication.
PROJECTED ACCRUAL: A total of 224 patients will be accrued for this study.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Diagnosis of a gynecologic malignancy
- Scheduled to undergo open abdominal/pelvic surgery (i.e., laparotomy) on the gynecologic oncology service at the University of California San Francisco Medical Center
- No failed epidural catheters (for patients choosing epidural analgesia)
- No lumbar epidurals (for patients choosing epidural analgesia)
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations| United States, California | |
| UCSF Helen Diller Family Comprehensive Cancer Center | Recruiting |
| San Francisco, California, United States, 94115 | |
| Contact: Clinical Trials Office - UCSF Helen Diller Family Comprehensi 877-827-3222 | |
| Study Chair: | Lee-may Chen, MD | University of California, San Francisco |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00295945 History of Changes |
| Other Study ID Numbers: | CDR0000459963, UCSF-03423, UCSF-H10588-24197-02 |
| Study First Received: | February 23, 2006 |
| Last Updated: | July 13, 2011 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
pain perioperative/postoperative complications stage III cervical cancer recurrent cervical cancer stage IB cervical cancer stage IIB cervical cancer stage IVB cervical cancer stage IA cervical cancer stage IIA cervical cancer stage IVA cervical cancer stage I endometrial carcinoma stage II endometrial carcinoma stage III endometrial carcinoma stage IV endometrial carcinoma recurrent endometrial carcinoma |
stage I uterine sarcoma stage II uterine sarcoma stage III uterine sarcoma stage IV uterine sarcoma recurrent uterine sarcoma ovarian sarcoma recurrent ovarian epithelial cancer recurrent ovarian germ cell tumor stage IV ovarian epithelial cancer stage IV ovarian germ cell tumor ovarian stromal cancer recurrent fallopian tube cancer stage IA fallopian tube cancer stage IB fallopian tube cancer stage IC fallopian tube cancer |
Additional relevant MeSH terms:
|
Endometrial Neoplasms Uterine Cervical Neoplasms Ovarian Neoplasms Postoperative Complications Fallopian Tube Neoplasms Adenoma Sarcoma Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Diseases Genital Diseases, Female Uterine Cervical Diseases |
Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Endocrine System Diseases Gonadal Disorders Pathologic Processes Fallopian Tube Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Hydromorphone Fentanyl Ropivacaine Analgesics, Opioid Analgesics |
ClinicalTrials.gov processed this record on May 16, 2013